Share-based Payment Arrangement, Expense of C4 Therapeutics, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
C4 Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • C4 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,593,000, a 48% decline year-over-year.
  • C4 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $23,327,000, a 16% decline year-over-year.
  • C4 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $29,662,000, a 8.9% increase from 2023.
  • C4 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $27,235,000, a 9.3% decline from 2022.
  • C4 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $30,016,000, a 40% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

C4 Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $23,327,000 $4,593,000 -$4,238,000 -48% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $27,565,000 $4,992,000 -$1,389,000 -22% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $28,954,000 $5,507,000 -$708,000 -11% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $29,662,000 $8,235,000 +$1,876,000 +30% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $27,786,000 $8,831,000 +$631,000 +7.7% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $27,155,000 $6,381,000 -$44,000 -0.68% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $27,199,000 $6,215,000 -$36,000 -0.58% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $27,235,000 $6,359,000 -$560,000 -8.1% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $27,795,000 $8,200,000 +$2,189,000 +36% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2023 Q1
Q2 2023 $25,606,000 $6,425,000 -$1,723,000 -21% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2023 Q1
Q1 2023 $27,329,000 $6,251,000 -$2,687,000 -30% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2023 Q1
Q4 2022 $30,016,000 $6,919,000 +$566,000 +8.9% 01 Oct 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q3 2022 $29,450,000 $6,011,000 -$75,000 -1.2% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q1
Q2 2022 $29,525,000 $8,148,000 +$2,920,000 +56% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q1
Q1 2022 $26,605,000 $8,938,000 +$5,093,000 +132% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $21,512,000 $6,353,000 +$3,634,000 +134% 01 Oct 2021 31 Dec 2021 10-K 23 Feb 2023 2022 FY
Q3 2021 $17,878,000 $6,086,000 +$5,650,000 +1296% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $12,228,000 $5,228,000 +$5,067,000 +3147% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $7,161,000 $3,845,000 +$3,729,000 +3215% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $3,432,000 $2,719,000 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $436,000 -$191,000 -30% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $161,000 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $116,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q3 2019 $627,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3

C4 Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $29,662,000 +$2,427,000 +8.9% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $27,235,000 -$2,781,000 -9.3% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $30,016,000 +$8,504,000 +40% 01 Jan 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
2021 $21,512,000 +$18,080,000 +527% 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2023 2022 FY
2020 $3,432,000 +$1,790,000 +109% 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
2019 $1,642,000 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.